Cullinan Therapeutics (CGEM) Stock Price, Quote, News & History | Benzinga

Cullinan Therapeutics Inc (CGEM) Stock Price, Quote, News & History

CGEMNASDAQ

Trade with Public

Trade with Public

$21.86

1.024.92%

Last update: Aug 19, 1:30 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$21.58

Close

-

Volume / Avg.

231.35K / 981.80K

Day Range

$21.22 - $21.95

52 Wk Range

5.68 - 21.22

Market Cap

$1.41B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

77

Short Interest

22.19%

Days to Cover

19.17

Recent Cullinan Therapeutics, Inc. News

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Vandana Singh

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500 index, while Real Messenger Corp (NASDAQ: RMSG) experienced a significant decline. Other gainers in pre-market trading include Dreamland Ltd (NASDAQ: TDIC), Gamehaus Holdings Inc (NASDAQ: GMHS), Nurix Therapeutics Inc (NASDAQ: NRIX), SmartKem Inc (NASDAQ: SMTK), Mountain Lake Acquisition Corp (NASDAQ: MLAC), Battalion Oil Corp (NASDAQ: BATL), Qtrex Quantum Ltd (NASDAQ: QTEX), Bone Biologics Corp (NASDAQ: BBLG), and Cullinan Therapeutics Inc (NASDAQ: CGEM).

Avi Kapoor

Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like Cabaletta Bio Inc, Celcuity Inc, and Xerox Holdings Corp.

Avi Kapoor

Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-159.25M

Investing Cash Flow (TTM)

162.88M

Financing Cash Flow (TTM)

2.19M

Free Cash Flow (TTM)

-159.30M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

5.82M

Analyst Trends and Forecast

3

May

2

Jun

1

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.01B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.17

Earnings Yield % (TTM)

-14.92%

Earnings Yield % (FWD)

-16.26%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.00

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$78.64M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$21.58

Close

-

Volume / Avg.

231.35K / 981.80K

Day Range

$21.22 - $21.95

52 Wk Range

5.68 - 21.22

Market Cap

$1.41B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

77

Short Interest

22.19%

Days to Cover

19.17

About

Sector

Health Care

Industry

Biotechnology

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is b...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cullinan Therapeutics (CGEM) stock?

A

You can purchase shares of Cullinan Therapeutics (NASDAQ:CGEM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cullinan Therapeutics (CGEM) competitors?

A

Other companies in Cullinan Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Cullinan Therapeutics (CGEM) stock?

A

Cullinan Therapeutics has a consensus price target of $29.67.

Q

What is the current price for Cullinan Therapeutics (CGEM)?

A

The stock price for Cullinan Therapeutics (NASDAQ: CGEM) is $21.865 last updated August 19, 2026 at 1:30 PM EDT.

Q

Does Cullinan Therapeutics (CGEM) pay a dividend?

A

There are no upcoming dividends for Cullinan Therapeutics.

Q

When is Cullinan Therapeutics (NASDAQ:CGEM) reporting earnings?

A

Cullinan Therapeutics does not have any upcoming earnings scheduled.

Q

Is Cullinan Therapeutics (CGEM) going to split?

A

There is no upcoming split for Cullinan Therapeutics.

Q

What sector and industry does Cullinan Therapeutics (CGEM) operate in?

A

Cullinan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.